# Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults

> **NCT00696891** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 380 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HBV-MPL vaccine
- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00696891
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-06
- **Primary completion:** 1999-05
- **Final completion:** —
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2008-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00696891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00696891, "Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00696891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*